tbuckley/cabot-search huggingface dataset:
Early introduction of palliative care for children with solid tumors.
Authors: Karen S. Fernandez, Rober J. Lucia, Rachel Buchheit, Michele J. Holman, Penelope Sandiford, Laura M. Sollenberger
Journal: Journal of Clinical Oncology (2014)

23 Background: Patients with solid tumors (ST) have the highest rate of relapse and mortality among pediatric oncology. Many patients suffer from acute and chronic therapy-related toxicity that have major implications in the patients’ lives. An early introduction of palliative care consultation (PCC) for patients with ST was implemented in 2012. Objectives: To assess the impact of the early introduction of PCC for children with ST on 1) Facilitation of interdisciplinary meetings (IDM) and goals of care 2) Counseling support including coping, advocacy, self-care, 3) Grieving, 4) End-of-life decision making/planning, and 5) Bereavement. Methods: An audit of all PCC from November/2012 to May/2014 was performed. Newly diagnosed patients with high risk ST (metastatic disease, need for HSCT or risk for relapse of &gt; 30%) were eligible for early PCC (36/44). Patients with brain tumors were excluded (19). Counselors were introduced to the patient/family at diagnosis. The perception of the intervention was explored among physicians and counselors. Results: 29/35 patients (72%) were offered early PCC, 1 declined the intervention. 17/29 developed disease relapse or progression (58%), 11/17 died. 9/29 had high risk ST without relapse (31%), 6/29 had loss of physical function (21%), 5/29 had other chronic diseases (17%). 20 had IDM for re-direction of goals of care. 25 (86%) received at least 1 of 3 counseling aspects. 20 received grieving support during treatment (6 due to loss of physical function, 4 during relapse and 11 during the dying process). 11 received end-of-life and bereavement support. Median number of visits/patient was 14. Pediatric oncologists felt early PCC favored effective communication between patients/families and medical teams, counselors felt early PCC was critical for rapport and trust building for an effective and productive professional relationship that strengthen the continuity of care. Conclusions: Early PCC for children with ST is feasible, and well-accepted by patients/families and physicians. It facilitates the comprehensive care of patients with ST throughout the disease trajectory.
Abstract 14189: Risk Prediction for Adverse Events During Initiation of Sotalol and Dofetilide for the Treatment of Atrial Fibrillation
Authors: Kartik Agusala, Adam C Oesterle, Tim W Caprio, Haris Subacius, Rod S Passman
Journal: Circulation (2013)

Introduction: Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and recommended for sotalol (SL) particularly if proarrhythmia risk factors are presen...
The significance of radiotherapy for adenocarcinoma of uterine cervix
Authors: M. Shimada, J. Kigawa, N. Terakawa, R. Nishimura, T. Takano, N. Yaegashi, K. Takehara, M. Suzuki, Y. Yokoyama, M. Hiura
Journal: Journal of Clinical Oncology (2007)

5590 Background: We conducted the present study to determine the significance of radiotherapy for cervical adenocarcinoma. Methods: A total of 1,133 patients with cervical cancer, who underwent radiotherapy in 7 institutes between 1996 and 2005, were enrolled in this study. There were 966 squamous cell carcinoma (SCC) and 167 adenocarcinoma (AC). The mean age of patients with AC was 53.6 (range: 28–81) and 55.9 (range: 22–92) for SCC. Patients were distributed as follows: 370 in stage 1b, 116 in stage IIa, 344 in stage IIb, 16 in stage IIIa, 240 in stage IIIb, and 47 in stage IVa. All patients were identified with the medical records. Of 1,133 patients, 544 received radiotherapy as primary treatment, and 589 underwent adjuvant radiotherapy. Results: Regarding primary treatment, the 5-year survival rate for AC was 41.8% and that for SCC was 62.5% (p=0.0172). The rate of refractory or recurrence for patients with AC was significantly higher than that for SCC (53.3% vs. 33.3%, p=0.0068). Patients with AC more commonly showed recurrence inside irradiated field compared with SCC (83.3% vs. 58.2%, p=0.0240). The outcome for patients with AC was significantly worse compared with SCC in adjuvant treatment (5-year survival rate: 27.5% vs. 45.4%, p=0.0434). Recurrence for AC were significantly higher observed than that for SCC (40.0% vs. 24.7%, p=0.0008). The incidence of recurrence inside irradiated field and lymph node involvement did not differ between AC and SCC (30.1% vs. 43.8%, 46.7% vs. 44.0%). Conclusions: Cervical adenocarcinoma had poorer prognosis because of its low radiosensitivity compared with SCC. New strategy for cervical adenocarcinoma should be necessary. No significant financial relationships to disclose.
Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer
Authors: C. J. Dalsania, A. Hageboutros, E. Harris, K. Krieger, C. Vora, J. Stevenson
Journal: Journal of Clinical Oncology (2007)

18163 Background: A randomized phase III trial has demonstrated the efficacy and safety of high dose bevacizumab (15 mg/kg) with carboplatin and paclitaxel in previously untreated advanced nonsquamous NSCLC (Sandler et al, NEJM 2006). Pemetrexed has also shown significant activity in advanced NSCLC. Clinical investigation of combination bevacizumab (BEV), pemetrexed (PEM) and carboplatin (CARBO) is therefore of interest in this population. Methods: Phase II, open label study in stage IIIB/IV NSCLC: eligible patients have non- squamous histology and no prior chemotherapy, brain metastasis, gross hemoptysis, tumor proximity to major vessels, uncontrolled hypertension or anticoagulation. All patients receive PEM (500 mg/m 2 ), CARBO (AUC 6) and BEV (15 mg/kg) every 21 days. Patients are pretreated with vitamin B12 1,000 mcg every 9 weeks and folic acid 1 mg daily. Responses are assessed every 2 cycles. Patients with CR, PR or SD receive maximum of 6 cycles followed by BEV (15 mg/kg) maintenance. Our primary objective is to determine time to progression and secondary objectives include response rate, overall survival, and safety of the combination. Results: 14 patients (9 female/ 5 male; median age 62 years; range 34–77; 2 stage IIIB/12 stage IV, all ECOG PS 0 or 1) have been entered. Median number of cycles received is 5.5 (range 2 - 15). 12 patients are evaluable for response. 9 patients continued to have disease control at a median duration of 20.2 weeks (range 5–52) with 6 PRs and 3 SDs (response rate 60%; disease control rate 75%). 5 patients proceeded to BEV maintenance with 2 still ongoing. Overall survival data is immature to date. Toxicity data is available for all patients. Grade 3/4 toxicities have included neutropenia (4), nausea/vomiting (2), BEV related allergic reaction (1) and epistaxis (1). Conclusions: Combination BEV, PEM and CARBO is safe, well tolerated and shows promising activity to date. The regimen is not associated with alopecia, neuropathy or arthralgias/myalgias, and is conveniently administered. Enrollment continues and updated results will be presented. No significant financial relationships to disclose.
Evaluation of PET imaging in treatment decision making for early stage head and neck squamous cell cancer
Authors: R. Dulala, J. L. Campian, S. Dubner, D. Frank, E. Gabalski, A. Thomas, M. Akerman, B. Mehrotra
Journal: Journal of Clinical Oncology (2009)

e17017 Background: Positron emission tomography (PET) scanning is widely used in staging of patients (pts.) with head and neck squamous cell cancers (HNSCC). However, the role of PET scan in pts. with early stage disease and clinically negative nodes remains controversial. The purpose of our study was to correlate preoperative PET scan findings in early stage disease with operative pathological findings of neck dissection. Methods: A retrospective review of medical records of all pts. treated at Long Island Jewish Medical Center with T1N0 HNSCC from 2002 to 2008 was undertaken. Institutional Review Board approval was obtained for this study. Eligibility criteria included: clinically staged T1N0, documented pre-operative PET scans and primary surgical management including a neck lymph node dissection as part of initial treatment. Data collected included age, gender, physical examination findings, PET scan results, operative pathology and modalities of treatment. Results: Sixty six pts with early stage T1N0 HNSCC were identified. Twelve of sixty six pts met eligibility criteria for this study. Median age was 61 years (range: 27 to 84 yrs), M:F ratio was 1:1. Primary sites of tumor were: tongue (n = 8) 67%; oral cavity (n = 3) 25%; larynx (n = 1) 8%. Preoperative PET scan was positive at primary sites in all pts (n = 12). Additionally, PET positivity was noted in regional lymph node sites in six of twelve pts. Operative pathology confirmed tumor presence in all primary sites. However, nodal involvement was not found in any pt. Median numbers of lymph nodes dissected were 25 (range:13–34). Based on these clinical data, the calculated statistical parameters for preoperative PET scan in detecting occult neck lymph node metastases were: negative predictive value: 100%; positive predictive value: 50%: specificity: 50%; sensitivity: 0%. Conclusions: The clinical application of PET scans in early stage (T1N0) HNSCC may be limited by its high false positive rate. A high negative predictive value suggests that a negative result can exclude metastatic lymph nodes involvement in this group of pts. with early stage disease. Correlation with SUV values of the PET scans and comparisons between the relative PET avidity of the primary tumors and the nodal uptake are ongoing. No significant financial relationships to disclose.
An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)
Authors: Christine I. Chen, Susi Snitzler, Trina Wang, Harminder Paul, Lisa W Le, Ellen Nong Wei, Anthea Lau, Deborah A Smith, Michelle Brown, James B Johnston, Suzanne Trudel
Journal: Blood (2013)
Abstract 13462: Cardiac Myosin Binding Protein-C Phosphorylation is Essential for Normal Diastolic Function
Authors: Yang Liu, Mohamed I Abdalla, Himakarnika Alluri, Colby Souders, Troy A Baudino, Patricia A Powers, Bindiya G Patel, Chad M Warren, John R Solaro, Richard L Moss, Carl W Tong
Journal: Circulation (2012)

Heart failure with preserved ejection fraction (HFpEF) is a primarily diastolic dysfunction disease for which there is no effective treatment. Cardiac myosin binding protein-C (MyBPC3) is a thick f...
Secondary malignancies after bone marrow transplantation in adults.
Authors: R Lowsky, J Lipton, G Fyles, M Minden, J Meharchand, I Tejpar, H Atkins, S Sutcliffe, H Messner
Journal: Journal of Clinical Oncology (1994)

The records of 557 consecutive adult recipients of allogeneic-related and -unrelated and syngeneic bone marrow transplants (BMTs) were reviewed to determine the incidence of secondary cancers.Four hundred fifty-six patients were transplanted for acute lymphocytic leukemia (ALL; n = 79), acute myelogenous leukemia (AML; n = 182), and chronic myelogenous leukemia (CML; n = 195); 42 patients were transplanted for aplastic anemia (AA) and 59 for a variety of other hematologic and nonhematologic disorders, malignant and nonmalignant. Conditioning regimens included high-dose chemotherapy with or without total-body irradiation (TBI). Statistical analyses determined the cumulative incidence of developing a secondary cancer and elucidated the associated risk factors. Complete records (1 to 24 years of follow-up) on all patients were available.Nine patients developed 10 secondary cancers for a cumulative actuarial risk of 12% (95% confidence interval [CI], 4.3 to 23.0) 11 years after transplant. The age-adjusted incidence of secondary cancer was 4.2 times higher than that of primary cancer in the general population. Eight of the 10 were epithelial in origin and three were cutaneous. TBI and acute graft-versus-host disease (GVHD) with a severity > or = grade II were associated with the development of any secondary cancer. On the other hand, chronic GVHD was a risk factor only for the development of secondary skin neoplasms.Adult recipients of BMT face a significant risk of developing a secondary malignancy. Their risk is similar to that of other patients with hematologic malignancies who are treated with chemoradiotherapy only. Epithelial tumors, rather than the more commonly reported Epstein-Barr virus (EBV)-associated lymphomas, were most common. The fact that we did not routinely use T-cell-depleted marrow grafts nor anti-T-cell immunoglobulin for the treatment of acute GVHD may explain this variance.
The efficiency of Langerhans' cell hystioctosis treatment (3 years follow-up)
Authors: Olga Baranova, Alexandra Speranskaja, Ivetta Dvorakovskaya, Elena Dembo-Smeathon, Dali Dzadzua
Journal: European Respiratory Journal (2011)

Aim:  To evaluate the efficiency of Langerhans9 cell hystiocytosis (LCH) treatment for 3years follow-up.   Methods:  38 patients (pts) with LCH confirmed by immunohistochemistry (IHC) research with monoclonal antibodies CD1a, S-100, LCA, CD68, Ki67, p53, Bax, Bcl-2, cpp32. The basic group (30 pts) was treated with systemic corticosteroids and cytostatics, control group (8 pts) did not receive treatment. All pts were subjected to clinical and radiological examinations and pulmonary function tests (PFTs).   Results:  After 3 yrs clinical improvement was noted only in 4 pts (0,17) of basic group, in 16 pts (0,53) clinical picture was stable, in 10 pts clinical deterioration was observed. From them 6 pts complained of increased dyspnea, in 2 cases involvement of other organs was found, 1 pt lost weight, 1 pt complained of increased cough. On CT improvement was found in 11 pts (0,37). In 13 pts CT picture was stable. Deterioration of CT picture was noted in 6 pts (0,2). PFTs improved in comparison with pre-treatment period only in 2 pts. PFTs were stable in 12 pts (0,4), in 15 pts PFTs were deteriorated. After 3 yrs of natural course LCH PFTs worsened in all pts of control group. Clinical deterioration was observed in 50% of pts, and radiological (CT) deterioration – in 1 pt. The radiological symptoms were most stable: in 6 pts (0,74) no changes were noted. This is probably the evidence of inadequate sensitivity of CT for the follow-up of pts with LCH.   Conclusions:  1. After 3 yrs treatment improvement or stabilisation of clinical and radiological data and PFTs was observed in 50% of pts. 2. These data show sensitivity of PFTs for assessment of disease course and treatment efficiency.
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Authors: G Bacci, S Ferrari, N Delepine, F Bertoni, P Picci, M Mercuri, P Bacchini, A Brach del Prever, A Tienghi, A Comandone, M Campanacci
Journal: Journal of Clinical Oncology (1998)

PURPOSE In osteosarcoma of the extremity, a strong correlation between chemotherapy-induced necrosis and prognosis has been reported. The aim of this study was to investigate the possible factors that influence histologic response to primary chemotherapy. PATIENTS AND METHODS In 272 patients with high-grade osteosarcoma of the extremity preoperatively treated with high-dose methotrexate (HDMTX), cisplatin (CDP), and doxorubicin (ADM), the histologic response to chemotherapy was evaluated and graded as complete (no viable tumor cells) or incomplete (persistence of viable tumor cells). Several factors, such as metastatic disease to the lung at diagnosis, sex, age, site and tumor volume, histologic subtype, serum alkaline phosphatase, lactate dehydrogenase (LDH), and methotrexate (MTX) pharmacokinetics were investigated to test their predictive significance on histologic response. RESULTS Fifty-one patients with localized disease (20.6%) and none of the 25 patients with metastatic disease at presentation had a complete histologic response (P = .006). After multivariate analysis, performed on patients with localized disease only, MTX serum peak (&gt; or = 700 micromol/L) and histologic subtype were proven to be significant predictive factors of histologic response. A complete response was seen in 28.8% of patients with 700 micromol/L or greater MTX serum levels and in 9.9% of those patients with lower levels (P = .001). The chondroblastic subtype was less responsive (6.1% of complete response), compared with the osteoblastic (16.3%), fibroblastic (33.3%), and telangiectatic (42.3%). CONCLUSION Patients with metastatic osteosarcoma and localized chondroblastic osteosarcoma have a reduced chemosensitivity to primary chemotherapy with MTX, CDP, and ADM. MTX serum peak significantly influences tumor necrosis. A dose adaptation of MTX is recommended to obtain a serum peak of 700 micromol/L or greater when MTX is infused in 6 hours.
Seasonality in violent suicide but not in nonviolent suicide or homicide
Authors: M Maes, P Cosyns, H Y Meltzer, F De Meyer, D Peeters
Journal: American Journal of Psychiatry (1993)

Previous studies have reported seasonal or monthly variation in suicide. The present study was conducted in order to determine seasonality and other significant rhythms in violent and nonviolent suicide, alone and together, and homicide.Data on suicide, violent suicide, nonviolent suicide, and homicide (categorized according to ICD-9) for all of Belgium for the period 1979-1987 were analyzed by means of spectral analyses.There was a significant seasonality for suicide but not homicide. Seasonality was present in violent but not in nonviolent suicide. The number of violent suicides increased with age and was more prominent in men. The violent suicide chronograms of younger and elderly persons were quite distinct in the occurrence of peaks in March-April and August, respectively, and lows in December-January. There was no significant relationship between violent suicide and homicide.Seasonality in suicide is determined by significant circannual rhythms in violent suicides, which differ between younger and elderly persons.
Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer.
Authors: J Sharma, D D Von Hoff, G R Weiss
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.11.2288 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8229147 Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer. J SharmaxJ SharmaSearch for articles by this author , D D Von HoffxD D Von HoffSearch for articles by this author , G R WeissxG R WeissSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.11.2288 PDF "Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer.." Journal of Clinical Oncology, 11(11), pp. 2288–2289© 1993 by American Society of Clinical Oncology
Phase II study of irinotecan (irin) and temozolomide (TMZ) in breast cancer patients with brain metastases that have progressed after stereotactic radiosurgery (SRS) or whole brain radiation (WBRT)
Authors: M. Melisko, J. Lyandres, J. Scott, J. W. Park, H. S. Rugo
Journal: Journal of Clinical Oncology (2008)

1103 Background: Brain metastases are an increasing problem in breast cancer. There are limited options for central nervous system (CNS) disease that has progressed after radiation therapy. Methods: A phase II study was initiated to evaluate the safety and efficacy of the combination of irinotecan and TMZ in breast cancer patients with brain metastases progressing after radiation. Irinotecan is administered at a dose of 125 mg/m2 intravenously every other week with TMZ 100 mg/m2 orally on days 1–7 and 15- 21. Objectives of the study are to evaluate the response rate and time to progression systemically and in the CNS and to determine toxicities associated with the combination. Brain MRI and other scans (CT, bone scan) were performed at 8-week intervals to assess response systemically and in the CNS. Results: 6 pts have been treated to date (median age 60, range 39–83); median number of prior chemo regimens = 3 (range 0–6). 3 pts received WBRT only, 1 pt received SRS only, and 2 pts received both WBRT and SRS. Related Aes include neutropenia (2 pts, grade 1–2; 1 pt grade 3 requiring growth factor support and dose reduction), diarrhea (3 pts, grade 1), nausea (5 pts, grade 1- 2), vomiting (3 pts, grade 1–2), fatigue (4 pts, grade 1), oral mucositis (4 patients, grade 1). 1 pt was hospitalized for a right hip fracture requiring surgery. At the week 8 evaluation, 3 of 4 evaluable pts had stable disease (SD). One pt has a partial response in the brain at week 46. 4 of the 6 patients remain on study. Biomarker data including circulating tumor cells in blood (all pts) and cerebrospinal fluid (1 pt) will be presented. Conclusions: The combination of irinotecan and TMZ is well tolerated in patients with progression of breast cancer brain metastases and has shown preliminary evidence of efficacy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Schering-Plough Pfizer Pfizer
Abstract 12036: Long-Term Outcome of Children Requiring Prolonged Intensive Care After Cardiac Surgery: Melbourne Experience
Authors: P Namachivayam, J Millar, Y d'Ydekem, M Cheung, W Butt
Journal: Circulation (2013)

Introduction: The number of children who require prolonged ( 28days) intensive care unit (ICU) stay after cardiac surgery has increased in the last decade. Previous studies have identified risk fac...
Studies of the Cytochemistry of Nucleoproteins. IV. Characterization of a Granular Form of Ribonucleoprotein in the Cytoplasm2
Authors: Robert Love, George P. Studzinski, Allen M. Clark, Elliott R. Tressan
Journal: JNCI Journal of the National Cancer Institute (1965)

A number of physical and chemical procedures, known or likely to cause disaggregation of polysomes, prevent or reduce staining of a granular form of cytoplasmic ribonucleoprotein (RNP) in HeLa cells by the toluidine blue-molybdate (TBM) stain. Experimental modifications of the metabolism of the cell that decrease protein and ribonucleic acid synthesis, or are known to disaggregate polysomes, result in a disappearance of the granular cytoplasmic RNP. Evidence is presented to show that the stainability of the granular cytoplasmic RNP and one type of diffuse RNP in the cytoplasm depends on the state of aggregation of ribosomes to form large or small polysomal clusters, respectively. Diffuse staining of another type of cytoplasmic RNP by the TBM method appears to represent the composite staining of all types of RNP in the cell and is unrelated to the state of aggregation of ribosomes. Except in one instance, disappearance of the granular cytoplasmic RNP is preceded or accompanied by loss of RNP from minute spherical structures in the nucleoli (nucleolini). The results suggest that this form of nucleolar RNP may be of the ribosomal precursor type.
Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration
Authors: G Alimena, E Morra, M Lazzarino, AM Liberati, E Montefusco, D Inverardi, P Bernasconi, M Mancini, E Donti, F Grignani
Journal: Blood (1988)